S
Serge Gauthier
Researcher at McGill University
Publications - 715
Citations - 61038
Serge Gauthier is an academic researcher from McGill University. The author has contributed to research in topics: Dementia & Disease. The author has an hindex of 93, co-authored 637 publications receiving 52775 citations. Previous affiliations of Serge Gauthier include Hamamatsu University School of Medicine & La Salle University.
Papers
More filters
Journal ArticleDOI
Clinical and biomarker trajectories in sporadic Alzheimer's disease: A longitudinal study.
Hui-Fu Wang,Xue-Ning Shen,Jie-Qiong Li,John Suckling,Chen-Chen Tan,Yan-Jiang Wang,Lei Feng,Can Zhang,Lan Tan,Qiang Dong,Jacques Touchon,Serge Gauthier,Jin-Tai Yu,Alzheimer’s Disease Neuroimaging Initiative +13 more
TL;DR: Amyloid beta deposition was identified to precede tau pathology and neurodegeneration in familial Alzheimer's disease (AD).
Journal ArticleDOI
Comparing tau status determined via plasma pTau181, pTau231 and [18F]MK6240 tau-PET
Cecile Tissot,Joseph Therriault,Peter Kunach,Andréa L Benedet,Tharick A. Pascoal,Nicholas J. Ashton,Thomas K. Karikari,Stijn Servaes,Firoza Z. Lussier,Mira Chamoun,Dana L. Tudorascu,Jenna Stevenson,Nesrine Rahmouni,Nina Margherita Poltronetti,V. Pallen,Gleb Bezgin,Min Su Kang,Sulantha Mathotaarachchi,Yi-Ting Wang,Jaime Fernandez Arias,Pâmela C. Lukasewicz Ferreira,J. P. Ferrari-Souza,Eugeen Vanmechelen,Kaj Blennow,Henrik Zetterberg,Serge Gauthier,Pedro Rosa-Neto +26 more
TL;DR: In this paper , the authors investigated agreement of tau status as determined by [18F]MK6240 tau-PET, plasma pTau181 and pTAU231, and compared the distribution among concordant and discordant groups in relation to diagnosis, Aβ status, APOEε4 status, [18 F]AZD4694 global SUVR, hippocampal volume and CSF pTaba181.
Journal ArticleDOI
Brain Metabolic Dysfunction in Early Neuropsychiatric Symptoms of Dementia
TL;DR: The frequency and associations of NPS with metabolic dysfunction in the AD continuum, including preclinical, prodromal, and dementia stages of AD are examined, and the validated neurobehavioral syndrome is presented.
Journal Article
Pharmacotherapy of mild cognitive impairment.
TL;DR: It is premature to recommend that acetylcholinesterase inhibitors be used systematically in amnestic MCI, but important lessons have been learned from studies in this prodromal stage of AD, allowing the testing of hypotheses for disease modification.